What is the CJC-1295 / Ipamorelin blend?
Short answer
The CJC-1295 / Ipamorelin blend pairs a modified analog of growth-hormone-releasing hormone with a five-amino-acid ghrelin-receptor agonist in one vial. CJC-1295 exists in two forms, with and without DAC, and the vial label must match the prescription. The published CJC-1295 studies were in healthy adults and measured hormone secretion, not clinical outcomes; no trial has tested the blend. It is a compounded medication, not FDA-approved for any use, and both components are prohibited in sport.
| Type | Two-compound blend: modified GHRH analog plus ghrelin-receptor agonist, in one vial |
|---|---|
| Also known as | CJC-1295 / Ipamorelin blend, CJC / Ipa stack, Mod GRF 1-29 / Ipamorelin |
| Evidence to date | CJC-1295: human pharmacokinetic and physiology studies in healthy adults. Ipamorelin: preclinical pharmacology. No trials of the combination |
| Form in this catalog | Subcutaneous injection, supplied already reconstituted, both peptides in one vial |
| Regulatory status | Compounded medication; neither component is FDA-approved for any use |
| Anti-doping | Both components prohibited at all times (WADA S2) |
| Key distinction | CJC-1295 with DAC (long-acting) versus without DAC (Mod GRF 1-29); the label must match the prescription |
| Prescription units | Written in micrograms, per peptide or for the whole blend; the calculator handles both |
| Study type | Sources |
|---|---|
| Human clinical trials | 2 |
| Other human studies | 1 |
| Animal and lab studies | 1 |
| Review articles | 0 |
What is in the CJC-1295 / Ipamorelin blend?
The CJC-1295 / Ipamorelin blend holds two synthetic peptides that signal the pituitary through different receptors. CJC-1295 is built on the first 29 amino acids of growth-hormone-releasing hormone, the part of the natural hormone that carries its activity, with several amino acids swapped to resist enzymatic breakdown. Ipamorelin is a pentapeptide, five amino acids long, that acts as a selective agonist at the ghrelin receptor and is classed as a growth hormone secretagogue.
The CJC-1295 half of the blend comes in two forms, and the difference matters. CJC-1295 with DAC carries a drug affinity complex, a chemical tail that binds to albumin in the blood so the molecule circulates for days rather than minutes; this is the long-acting version the published studies describe. CJC-1295 without DAC, often sold as Mod GRF 1-29, is the same modified GHRH fragment without that tail and is cleared quickly. A prescription names one of them, and the vial label must match it; the two are not interchangeable.
What has the CJC-1295 / Ipamorelin blend been studied for?
The CJC-1295 / Ipamorelin blend has never been tested as a combination in a published trial. The CJC-1295 literature among the studies cited here consists of two 2006 papers in healthy adults. One was a randomized, placebo-controlled study of pharmacokinetics and safety that measured growth hormone and insulin-like growth factor I secretion after the long-acting analog; the other was a physiology study in healthy men reporting that pulsatile growth hormone secretion persisted during continuous stimulation. Both measured hormone levels, not clinical outcomes.
Ipamorelin brings a 1998 preclinical pharmacology paper and a 2014 randomized proof-of-concept trial in postoperative ileus after bowel resection that did not meet its primary endpoint. So the honest summary of this blend's evidence is: hormone-level data for one component in healthy volunteers, animal and cell data plus a negative surgical trial for the other, and no human data on the pair.
| Component | Type of evidence | What the studies examined |
|---|---|---|
| CJC-1295 (with DAC) | Randomized controlled trial (healthy adults; pharmacokinetics and safety) | Growth hormone and IGF-I secretion after a long-acting GHRH analog, 2006 |
| CJC-1295 (with DAC) | Human physiology study (healthy men) | Whether pulsatile growth hormone secretion persisted during continuous stimulation, 2006 |
| Ipamorelin | Preclinical pharmacology | Growth hormone release and receptor selectivity in animal and cell models, 1998 |
| Ipamorelin | Randomized proof-of-concept trial (postoperative ileus) | Bowel function after resection; primary endpoint not met, 2014 |
| The combination | No trials | Not studied together |
Get CJC-1295 / Ipamorelin prescribed, pre-mixed
How is the CJC-1295 / Ipamorelin blend prescribed?
The CJC-1295 / Ipamorelin blend is prescribed through Peptides.build as a compounded medication: a licensed US provider reviews an online intake and, if appropriate, writes a prescription that a licensed 503A pharmacy fills by dissolving both peptides in one vial. The vial ships already reconstituted with the strength of each peptide on the label; most CJC-1295 / Ipamorelin vials hold the two in equal amounts, so a vial labelled with one total weight usually contains half of each.
The CJC-1295 / Ipamorelin blend is the only form of either peptide in this catalog; neither CJC-1295 nor ipamorelin is sold on its own here. The sibling blend swaps CJC-1295 for tesamorelin. Which pairing, if either, suits a patient is a provider decision at intake; the dose and schedule are set by the provider and not published here.
Is the CJC-1295 / Ipamorelin blend FDA-approved or allowed in sport?
The CJC-1295 / Ipamorelin blend is not FDA-approved for any use, and neither of its components is. No branded CJC-1295 or ipamorelin product has been approved in the US, so the blend reaches patients only as a compounded medication prescribed for an individual, and compounded medications are not reviewed or approved by the FDA the way mass-manufactured drugs are.
The CJC-1295 / Ipamorelin blend is prohibited in sport at all times. The World Anti-Doping Agency names CJC-1295 under S2 among growth hormone releasing factors and ipamorelin under S2 among growth hormone secretagogues. Drug-tested athletes should check with their governing body before a prescription is filled.
How are CJC-1295 / Ipamorelin doses measured?
CJC-1295 / Ipamorelin prescriptions are written in micrograms, either as an amount of one peptide per injection or as an amount of the whole blend, and the vial label may print one strength per peptide or a single total. A per-peptide dose has to be divided by that peptide's own concentration, and a whole-blend dose by the total, or the draw comes out at half or double what was meant. The free CJC-1295 / Ipamorelin calculator on this site handles both ways of writing a prescription and shows how much of the second peptide comes with each draw. It is arithmetic only and does not recommend a dose.
Prescribed CJC-1295 / Ipamorelin vs research peptides: what is different?
Prescribed CJC-1295 / Ipamorelin is not a research chemical. It is a prescription medication: a licensed US provider reviews your intake first, and a licensed 503A pharmacy compounds it for you by name. Vials sold online as “research use only” skip both steps. What you pay for here is that review, a pharmacy you can name, and a label that says what is in the vial.
A research seller’s certificate of analysis is a document the seller controls: it chooses the lab and the sample, and a PDF can be reused, edited or re-dated. No regulator checks it.
| Point | Prescribed through Peptides.build | Research use only |
|---|---|---|
| Access | Online intake reviewed by a licensed US provider; prescribed only when appropriate. | No prescription and no clinical review of whether it suits you. |
| How it's labeled | A prescription medication compounded for you by name. | Commonly sold labeled “research use only, not for human consumption.” |
| Who prepares it | A licensed 503A US compounding pharmacy under state and federal oversight. | Unregulated suppliers, often with no verifiable chain of custody. |
| Testing | Third-party tested. | Certificates of analysis are self-reported when provided at all. |
| Purity and identity | Prepared to a prescription for a specific patient. | Purity, strength, and even identity are unverified by any independent party. |
This compares two care models, not two products. Compounded medications are not FDA-approved, and we do not claim otherwise. What a prescription adds is a licensed provider deciding whether a protocol is appropriate for you and a licensed pharmacy preparing it. Read the full guide to research vs prescription peptides.
CJC-1295 / Ipamorelin FAQ
What is the difference between CJC-1295 with DAC and without DAC?
With DAC, CJC-1295 carries a chemical tail that binds albumin and keeps it circulating for days; this is the long-acting form the published healthy-adult studies describe. Without DAC, often called Mod GRF 1-29, the same modified GHRH fragment is cleared quickly. A prescription names one form, and the vial label must match it.
Has the CJC-1295 / Ipamorelin blend been tested in a clinical trial?
No. The CJC-1295 studies were in healthy adults and measured growth hormone and IGF-I secretion, not clinical outcomes. Ipamorelin has preclinical work and one negative trial in postoperative ileus. No study has tested the two together.
Is the CJC-1295 / Ipamorelin blend FDA-approved?
No. Neither CJC-1295 nor ipamorelin is FDA-approved for any use. The blend is a compounded medication prepared by a licensed 503A pharmacy after a prescription, and compounded medications are not FDA-approved.
Is the CJC-1295 / Ipamorelin blend banned in sport?
Yes. The World Anti-Doping Agency prohibits both components at all times under S2, CJC-1295 as a growth hormone releasing factor and ipamorelin as a growth hormone secretagogue. Drug-tested athletes should check with their governing body.
Is CJC-1295 / Ipamorelin the same as growth hormone?
No. Both peptides are signals that prompt the pituitary to release its own growth hormone, through two different receptors. Neither contains growth hormone, and anti-doping bodies classify them separately from growth hormone products.
How is the CJC-1295 / Ipamorelin blend different from Tesamorelin / Ipamorelin?
Both blends pair ipamorelin with a GHRH analog; the difference is which one. CJC-1295 is a modified GHRH fragment studied for hormone secretion in healthy adults, while tesamorelin is a full-length stabilized GHRH analog with randomized trials in HIV-associated abdominal fat accumulation and a brand-name approval in that indication.
CJC-1295 / Ipamorelin through Peptides.build
A licensed US provider reviews a short online intake and decides whether a protocol is appropriate. A US 503A pharmacy prepares it already reconstituted, labels the concentration and ships it cold-chain. Dosing is set by the provider and is not published on this site.
Start your CJC-1295 / Ipamorelin visit · from $183/mo- CJC-1295 / Ipamorelin protocol: pricing, who it is for, FAQ
- All performance protocols compared
- CJC-1295 / Ipamorelin Calculator: units, reconstitution and dosing chart
- What is ipamorelin?
- CJC-1295 vs tesamorelin: what is the difference?
- CJC-1295 / Ipamorelin vs Tesamorelin / Ipamorelin: what is the difference?
- What is the Tesamorelin / Ipamorelin blend?
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006. doi:10.1210/jc.2005-1536Study type: Randomized controlled trial (healthy adults; pharmacokinetics and safety)
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 2006. doi:10.1210/jc.2006-1702Study type: Human physiology study (healthy men)
- Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. doi:10.1530/eje.0.1390552Study type: Preclinical pharmacology
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014. doi:10.1007/s00384-014-2030-8Study type: Randomized controlled trial (postoperative ileus; primary endpoint not met)
Citations are listed with their study type so the evidence can be weighed. Review articles summarize other studies; animal and in vitro findings do not describe outcomes in people.
This article is educational and is not medical advice. CJC-1295 / Ipamorelin is not FDA-approved for any use, and compounded medications are not FDA-approved. No results are implied or guaranteed. Talk to a licensed provider about your own history before starting any protocol.